Gene therapy · Gene replacement · developed by Krystal Biotech
Beremagene geperpavec is a topical gene therapy based on a non-integrating, replication-incompetent herpes simplex virus type 1 vector that carries the human COL7A1 gene. After application to wounds, it transduces keratinocytes and fibroblasts, which then produce collagen VII to form anchoring fibrils. It is studied in dystrophic epidermolysis bullosa.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 29, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04917874 | Phase 3 | Dystrophic Epidermolysis Bullosa | Completed | KRYS |
| NCT04491604 | Phase 3 | Dystrophic Epidermolysis Bullosa | Completed | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DEB - Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →